Form 4: Xilio Therapeutics Executive Granted Stock Options

Christopher James Frankenfield, Chief Operating Officer of Xilio Therapeutics, Inc., was granted stock options for 208,000 shares on May 1, 2024.

Summary

• Christopher James Frankenfield, the Chief Operating Officer of Xilio Therapeutics, Inc., received a grant of stock options on May 1, 2024.
• The options allow him to purchase 208,000 shares of Xilio Therapeutics common stock at an exercise price of $1.08 per share.
• The options vest in monthly installments starting June 1, 2024, and continuing until May 1, 2028.
• The options expire on April 30, 2034.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a routine stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant (208,000 shares) and the vesting schedule (monthly over four years) appear to be within typical ranges for a COO at a company of Xilio Therapeutics' size and stage.
• Comparable companies such as Tango Therapeutics or Relay Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the COO to work towards increasing shareholder value.

Key Dates